SG10201913993QA - PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF - Google Patents
PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOFInfo
- Publication number
- SG10201913993QA SG10201913993QA SG10201913993QA SG10201913993QA SG10201913993QA SG 10201913993Q A SG10201913993Q A SG 10201913993QA SG 10201913993Q A SG10201913993Q A SG 10201913993QA SG 10201913993Q A SG10201913993Q A SG 10201913993QA SG 10201913993Q A SG10201913993Q A SG 10201913993QA
- Authority
- SG
- Singapore
- Prior art keywords
- pyrazin
- pyrrolo
- imidazo
- trifluoroethyl
- carboxamide
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562242797P | 2015-10-16 | 2015-10-16 | |
US201562267672P | 2015-12-15 | 2015-12-15 | |
US201662301537P | 2016-02-29 | 2016-02-29 | |
US201662352380P | 2016-06-20 | 2016-06-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10201913993QA true SG10201913993QA (en) | 2020-03-30 |
Family
ID=57209916
Family Applications (8)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201913989QA SG10201913989QA (en) | 2015-10-16 | 2016-10-17 | PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF |
SG10201913997WA SG10201913997WA (en) | 2015-10-16 | 2016-10-17 | PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF |
SG11201802990RA SG11201802990RA (en) | 2015-10-16 | 2016-10-17 | PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF |
SG10201913987UA SG10201913987UA (en) | 2015-10-16 | 2016-10-17 | PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF |
SG10201913999PA SG10201913999PA (en) | 2015-10-16 | 2016-10-17 | PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF |
SG10201913993QA SG10201913993QA (en) | 2015-10-16 | 2016-10-17 | PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF |
SG10201913986YA SG10201913986YA (en) | 2015-10-16 | 2016-10-17 | PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF |
SG10201913990RA SG10201913990RA (en) | 2015-10-16 | 2016-10-17 | PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF |
Family Applications Before (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201913989QA SG10201913989QA (en) | 2015-10-16 | 2016-10-17 | PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF |
SG10201913997WA SG10201913997WA (en) | 2015-10-16 | 2016-10-17 | PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF |
SG11201802990RA SG11201802990RA (en) | 2015-10-16 | 2016-10-17 | PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF |
SG10201913987UA SG10201913987UA (en) | 2015-10-16 | 2016-10-17 | PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF |
SG10201913999PA SG10201913999PA (en) | 2015-10-16 | 2016-10-17 | PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201913986YA SG10201913986YA (en) | 2015-10-16 | 2016-10-17 | PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF |
SG10201913990RA SG10201913990RA (en) | 2015-10-16 | 2016-10-17 | PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF |
Country Status (14)
Country | Link |
---|---|
US (34) | US20170129902A1 (en) |
EP (2) | EP4219503A1 (en) |
JP (4) | JP6770775B2 (en) |
KR (1) | KR20180081523A (en) |
CN (4) | CN116270645A (en) |
AU (3) | AU2016340167B2 (en) |
BR (2) | BR122022024925B1 (en) |
CA (2) | CA3123260A1 (en) |
HK (1) | HK1263380A1 (en) |
IL (2) | IL258654A (en) |
MX (2) | MX2018004605A (en) |
RU (1) | RU2018117889A (en) |
SG (8) | SG10201913989QA (en) |
WO (1) | WO2017066775A1 (en) |
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2836833A1 (en) | 1978-08-23 | 1980-04-10 | Volkswagenwerk Ag | INTERNAL COMBUSTION ENGINE WITH CYLINDERS IN TWO ROWS |
CN102711476B (en) | 2009-12-01 | 2014-12-03 | Abbvie公司 | Novel tricyclic compounds |
US11365198B2 (en) | 2015-10-16 | 2022-06-21 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
CN116270645A (en) | 2015-10-16 | 2023-06-23 | 艾伯维公司 | Process for preparing imidazo [1,2-a ] pyrrolo [2,3-e ] pyrazines and solid forms thereof |
US10550126B2 (en) | 2015-10-16 | 2020-02-04 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
US11512092B2 (en) * | 2015-10-16 | 2022-11-29 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
US11524964B2 (en) | 2015-10-16 | 2022-12-13 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
US11773106B2 (en) | 2015-10-16 | 2023-10-03 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
JP2020510016A (en) | 2017-03-09 | 2020-04-02 | アッヴィ・インコーポレイテッド | Methods for treating Crohn's disease and ulcerative colitis |
US11564922B2 (en) | 2017-03-09 | 2023-01-31 | Abbvie Inc. | Methods of treating crohn's disease and ulcerative colitis |
WO2019016745A1 (en) * | 2017-07-19 | 2019-01-24 | Dr. Reddy's Laboratories Limited | Alternate processes for the preparation of pyrrolidine derivatives |
PE20210402A1 (en) | 2018-03-30 | 2021-03-02 | Incyte Corp | TREATMENT OF SUPURATIVE HYDRADENITIS USING JAK INHIBITORS |
CN110872250B (en) * | 2018-08-31 | 2023-01-10 | 苏州鹏旭医药科技有限公司 | Two compounds, preparation methods thereof and application thereof in synthesis of ursitinib |
WO2020043033A2 (en) * | 2018-08-31 | 2020-03-05 | 苏州鹏旭医药科技有限公司 | Synthesis methods for upadacitinib and intermediate thereof |
CN112770756A (en) * | 2018-09-29 | 2021-05-07 | 苏州科睿思制药有限公司 | Udacetitinib crystal form and preparation method and application thereof |
CN111217819B (en) * | 2018-11-27 | 2021-05-14 | 杭州科巢生物科技有限公司 | Synthetic method of sepiatinib |
EP3891151A1 (en) | 2018-12-05 | 2021-10-13 | LEK Pharmaceuticals d.d. | Crystalline phosphate salt of selective jak1 inhibitor upadacitinib |
CN109369659B (en) * | 2018-12-06 | 2020-10-27 | 浙江师范大学 | Synthetic method of JAK inhibitor |
WO2020115213A1 (en) | 2018-12-07 | 2020-06-11 | Lek Pharmaceuticals D.D. | Solvate of a selective jak1 inhibitor |
CN109705011B (en) * | 2019-01-18 | 2021-02-19 | 浙江师范大学 | Synthetic method of Upacatinib intermediate and intermediate |
WO2020177645A1 (en) * | 2019-03-01 | 2020-09-10 | 苏州科睿思制药有限公司 | Upadacitinib crystal form and preparation method therefor and use thereof |
WO2020202183A1 (en) | 2019-03-29 | 2020-10-08 | Mylan Laboratories Limited | The process for the preparation of upadacitinib and its intermediates |
CN111909160A (en) * | 2019-05-09 | 2020-11-10 | 苏州鹏旭医药科技有限公司 | Upacatinib salt compound and preparation method thereof |
CN110229160A (en) * | 2019-06-11 | 2019-09-13 | 南京新酶合医药科技有限公司 | The preparation method of (5- tosyl -5H- pyrrolo- [2,3-b] pyrazine -2- base) urethanes |
CN110117245B (en) * | 2019-06-21 | 2021-03-02 | 浙江师范大学 | Synthetic method of JAK inhibitor intermediate |
WO2021005484A1 (en) * | 2019-07-11 | 2021-01-14 | Mankind Pharma Ltd. | Pyrrolidine compounds, its salt and use in the preparation of upadacitinib thereof |
CN110615753A (en) * | 2019-09-02 | 2019-12-27 | 南京新酶合医药科技有限公司 | Synthesis method of (3R,4S) -1-substituted-4-ethylpyrrole-3-carboxylic acid |
EP4037686A1 (en) | 2019-09-30 | 2022-08-10 | Abbvie Inc. | Treating spondyloarthritic and psoriatic conditions with upadacitinib |
CN111072543B (en) * | 2019-11-13 | 2021-06-04 | 北京海美桐医药科技有限公司 | Preparation method and application of (3R,4S) -4-ethylpyrrolidine-3-carboxylic acid compound |
EP4077276A1 (en) * | 2019-12-19 | 2022-10-26 | Curia Spain S.A.U. | Process and intermediates for the preparation of upadacitinib |
WO2021176473A1 (en) * | 2020-03-05 | 2021-09-10 | Mylan Laboratories Limited | A process for the preparation of upadacitinib and its intermediates |
WO2021244323A1 (en) * | 2020-06-05 | 2021-12-09 | 苏州科睿思制药有限公司 | Crystal form of upadacitinib, preparation method therefor, and use thereof |
KR20230038229A (en) | 2020-07-08 | 2023-03-17 | 크리스탈 파마슈티컬 (쑤저우) 씨오., 엘티디. | Crystalline form of upadacitinib, process for its preparation and use thereof |
WO2022044037A1 (en) | 2020-08-24 | 2022-03-03 | Mylan Laboratories Limited | An improved process for the preparation of upadacitinib intermediate |
EP4319743A1 (en) * | 2021-04-07 | 2024-02-14 | Abbvie Inc. | Cocrystals of upadacitinib |
CN114380837B (en) * | 2021-12-27 | 2023-06-30 | 上海邈金医药科技有限公司 | Compound with Janus kinase inhibition activity, composition comprising compound and application of compound |
WO2023131978A1 (en) * | 2022-01-06 | 2023-07-13 | Msn Laboratories Private Limited, R&D Center | Improved process for the preparation of upadacitinib |
WO2023138804A1 (en) | 2022-01-20 | 2023-07-27 | Renata Pharmaceutical (Ireland) Limited | Sustained release pharmaceutical composition of upadacitinib |
EP4215196A1 (en) | 2022-01-24 | 2023-07-26 | Abivax | Combination of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine and its derivatives with a jak inhibitor |
CN117285535B (en) * | 2023-11-27 | 2024-02-02 | 中节能万润股份有限公司 | Preparation method of Marpatinib intermediate and salified intermediate |
CN117285536B (en) * | 2023-11-27 | 2024-02-20 | 中节能万润股份有限公司 | Preparation method of Martinib intermediate |
CN117285537B (en) * | 2023-11-27 | 2024-02-06 | 中节能万润股份有限公司 | Preparation method of Marpatinib |
CN117447481A (en) * | 2023-12-23 | 2024-01-26 | 潍坊医学院 | Amorphous substance of Martinib-pyroglutamate and preparation method and application thereof |
Family Cites Families (128)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB716327A (en) | 1951-09-05 | 1954-10-06 | Ici Ltd | New heterocyclic compounds |
US3663559A (en) | 1969-12-03 | 1972-05-16 | Union Carbide Corp | Preparation of oxo-furo-pyridines from furylvinyl isocyanates |
ZA737247B (en) | 1972-09-29 | 1975-04-30 | Ayerst Mckenna & Harrison | Rapamycin and process of preparation |
US4053474A (en) | 1976-04-21 | 1977-10-11 | E. R. Squibb & Sons, Inc. | Pyrazolo[4,3-e][1,2,4]triazolo[4,3-c]pyrimidine |
US5605690A (en) | 1989-09-05 | 1997-02-25 | Immunex Corporation | Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor |
DE69033614T2 (en) | 1989-10-20 | 2001-04-19 | Kyowa Hakko Kogyo Kk | Condensed purine derivatives |
EP1418179A3 (en) | 1990-01-11 | 2006-03-08 | Isis Pharmaceuticals, Inc. | Compositions and methods for detecting and modulating rna activity and gene expression |
US6262241B1 (en) | 1990-08-13 | 2001-07-17 | Isis Pharmaceuticals, Inc. | Compound for detecting and modulating RNA activity and gene expression |
DE69231828T3 (en) | 1991-03-18 | 2008-06-19 | New York University | Specific anti-human tumor necrosis factor monoclonal and chimeric antibodies |
WO1992022552A1 (en) | 1991-06-14 | 1992-12-23 | The Upjohn Company | IMIDAZO[1,5-a]QUINOXALINES |
US5212310A (en) | 1991-12-19 | 1993-05-18 | Neurogen Corporation | Certain aryl fused imidazopyrimidines; a new class of GABA brain receptor ligands |
US5266698A (en) | 1992-04-30 | 1993-11-30 | Neurogen Corporation | Certain aryl and cycloalkyl fused imidazopyrazinediones; a new class of GABA brain receptor ligands |
US5306819A (en) | 1992-08-27 | 1994-04-26 | Neurogen Corporation | Certain aryl a cycloalkyl fused imidazopyrazinols; and new class of GABA brain receptor ligands |
JP3095175B2 (en) | 1992-11-13 | 2000-10-03 | アイデック ファーマシューティカルズ コーポレイション | Therapeutic use of chimeric and radiolabeled antibodies against human B lymphocyte restricted differentiation antigen for the treatment of B cell lymphoma |
AU681875B2 (en) | 1993-02-26 | 1997-09-11 | Schering Corporation | 2-benzyl-polycyclic guanine derivatives and process for preparing them |
US5733905A (en) | 1993-07-29 | 1998-03-31 | American Cyanamid Company | Tricyclic diazepine vasopressin antagonists and oxytocin antagonists |
US5736540A (en) | 1993-07-29 | 1998-04-07 | American Cyanamid Company | Tricyclic diazepine vasopressin antagonists and oxytocin antagonists |
IL112248A0 (en) | 1994-01-25 | 1995-03-30 | Warner Lambert Co | Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them |
US5547975A (en) | 1994-09-20 | 1996-08-20 | Talley; John J. | Benzopyranopyrazolyl derivatives for the treatment of inflammation |
RU2158127C2 (en) | 1994-12-23 | 2000-10-27 | Варнер-Ламберт Компани | Method for inhibiting epidermal growth factor receptor thyrosinekinase, nitrogen-containing tricyclic compounds and pharmaceutical composition for introducing epidermal growth factor receptor thyrosinekinase inhibitor like erb- b2, erb-b3 or erb-b4 and contraceptive composition |
US5753648A (en) | 1995-01-17 | 1998-05-19 | American Cyanamid Company | Tricyclic benzazepine vasopressin antagonists |
US5521173A (en) | 1995-01-17 | 1996-05-28 | American Home Products Corporation | Tricyclic benzazepine vasopressin antagonists |
US5763137A (en) | 1995-08-04 | 1998-06-09 | Agfa-Gevaert, N.V. | Method for making a lithographic printing plate |
US6090382A (en) | 1996-02-09 | 2000-07-18 | Basf Aktiengesellschaft | Human antibodies that bind human TNFα |
FR2742676B1 (en) | 1995-12-21 | 1998-02-06 | Oreal | TRANSPARENT NANOEMULSION BASED ON SILICON SURFACTANTS AND USE IN COSMETICS OR DERMOPHARMACY |
US5703244A (en) | 1996-11-21 | 1997-12-30 | Abbott Laboratories | Process for preparation of chiral 3-amino-pyrrolidine and analogous bicyclic compounds |
KR100573192B1 (en) | 1997-02-05 | 2006-04-24 | 머크 앤드 캄파니 인코포레이티드 | Process for the crystallization of a reverse transcriptase inhibitor using an anti-solvent and crystal forms of the same |
CA2322311C (en) | 1998-03-04 | 2009-10-13 | Bristol-Myers Squibb Company | Heterocyclo-substituted imidazopyrazine protein tyrosine kinase inhibitors |
KR20010075064A (en) | 1998-09-14 | 2001-08-09 | 로즈 암스트롱, 크리스틴 에이. 트러트웨인 | Branched alkyl pyrrolidine-3-carboxylic acids |
US6448253B1 (en) | 1998-09-16 | 2002-09-10 | King Pharmaceuticals Research And Development, Inc. | Adenosine A3 receptor modulators |
DE19853665B4 (en) | 1998-11-20 | 2005-06-30 | Siemens Ag | Vehicle communication system and method for exchanging data in a motor vehicle |
IL139197A0 (en) | 1999-10-29 | 2001-11-25 | Pfizer Prod Inc | Use of corticotropin releasing factor antagonists and related compositions |
TWI271406B (en) | 1999-12-13 | 2007-01-21 | Eisai Co Ltd | Tricyclic condensed heterocyclic compounds, preparation method of the same and pharmaceuticals comprising the same |
IL154310A0 (en) | 2000-08-07 | 2003-09-17 | Neurogen Corp | Heterocyclic compounds as ligands of the gabaa receptor |
GB0115393D0 (en) | 2001-06-23 | 2001-08-15 | Aventis Pharma Ltd | Chemical compounds |
GB0124299D0 (en) | 2001-10-10 | 2001-11-28 | Astrazeneca Ab | Crystal structure of enzyme and uses thereof |
US20040127492A1 (en) | 2002-02-19 | 2004-07-01 | Pharmacia Corporation | Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 |
US20030181488A1 (en) | 2002-03-07 | 2003-09-25 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof |
TW200400034A (en) | 2002-05-20 | 2004-01-01 | Bristol Myers Squibb Co | Pyrazolo-pyrimidine aniline compounds useful as kinase inhibitors |
WO2004032874A2 (en) | 2002-10-09 | 2004-04-22 | Scios Inc. | AZAINDOLE DERIVATIVES AS INHIBITORS OF p38 KINASE |
DE602004021558D1 (en) | 2003-01-17 | 2009-07-30 | Warner Lambert Co | 2-AMINOPYRIDINE SUBSTITUTED HETEROCYCLES AS INHIBITORS OF CELLULAR PROLIFERATION |
EP1460088A1 (en) | 2003-03-21 | 2004-09-22 | Biotest AG | Humanized anti-CD4 antibody with immunosuppressive properties |
AR044510A1 (en) | 2003-04-14 | 2005-09-14 | Merck & Co Inc | PROCEDURE AND INTERMEDIATES TO PREPARE CARBOXILIC ACIDS OF PIRROLIDINE |
US7176214B2 (en) | 2003-05-21 | 2007-02-13 | Bristol-Myers Squibb Company | Imidazo-fused oxazolo[4,5-β]pyridine and imidazo-fused thiazolo[4,5-β]pyridine based tricyclic compounds and pharmaceutical compositions comprising same |
US7169926B1 (en) | 2003-08-13 | 2007-01-30 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
ATE419242T1 (en) | 2003-10-09 | 2009-01-15 | Abbott Lab | PYRROLIDINYLUREA DERIVATIVES AS ANGIOGENESIS INHIBITORS |
US7592466B2 (en) | 2003-10-09 | 2009-09-22 | Abbott Laboratories | Ureas having antiangiogenic activity |
EP1753428A4 (en) | 2004-05-14 | 2010-09-15 | Abbott Lab | Kinase inhibitors as therapeutic agents |
AR049300A1 (en) | 2004-06-15 | 2006-07-12 | Schering Corp | MGLUR1 ANTAGONIST TRICICLIC COMPOUNDS AS THERAPEUTIC AGENTS |
US8039009B2 (en) | 2004-06-17 | 2011-10-18 | Forest Laboratories Holdings Limited | Modified release formulations of memantine oral dosage forms |
ES2341559T3 (en) | 2004-07-23 | 2010-06-22 | The Medicines Company (Leipzig) Gmbh | PIRIDO (3 ', 2': 4,5) HAVING (3,2-D) PYRIMIDINES AND PIRIDO (3 ', 2': 4,5) FURO (3,2-D) PIRIMIDINES REPLACED FOR USE AS INHIBITORS OF THE RELEASE OF PDA-4 AND / OR TNF-ALFA. |
KR20070053236A (en) | 2004-07-27 | 2007-05-23 | 에스지엑스 파마슈티컬스, 인코포레이티드 | Fused ring heterocycle kinase modulators |
US7626021B2 (en) | 2004-07-27 | 2009-12-01 | Sgx Pharmaceuticals, Inc. | Fused ring heterocycle kinase modulators |
CN100381175C (en) | 2004-10-09 | 2008-04-16 | 山西中医学院 | Microemulsion formulation and its preparation process |
NZ555566A (en) | 2004-11-22 | 2009-12-24 | Vertex Pharma | Pyrrolopyrazines and pyrazolopyrazines useful as inhibitors of protein kinases |
PT1838677E (en) | 2004-12-21 | 2009-11-16 | Arena Pharm Inc | Crystalline forms of (r)-8-chloro-1-methyl- 2,3,4,5-tetrahydro-1h-3-benzazepine hydrochloride |
CA2594425A1 (en) | 2005-01-14 | 2006-07-20 | Janssen Pharmaceutica N.V. | 5-membered annelated heterocyclic pyrimidines as kinase inhibitors |
ES2345997T3 (en) | 2005-01-14 | 2010-10-07 | Janssen Pharmaceutica Nv | PIRAZOLOPIRAMIDINAS AS INHIBITORS OF THE KINASAS OF THE CELL CYCLE. |
US20060183758A1 (en) | 2005-02-17 | 2006-08-17 | Cb Research And Development, Inc. | Method for synthesis of AZA-annelated pyrroles, thiophenes, and furans |
US8138173B2 (en) | 2005-04-01 | 2012-03-20 | 3M Innovative Properties Company | Pyrazolo[3,4-C]quinolines, pyrazolo[3,4-C]naphthyridines, analogs thereof, and methods |
US7737279B2 (en) | 2005-05-10 | 2010-06-15 | Bristol-Myers Squibb Company | 1,6-dihydro-1,3,5,6-tetraaza-as-indacene based tricyclic compounds and pharmaceutical compositions comprising same |
US7593820B2 (en) | 2005-05-12 | 2009-09-22 | Cytopia Research Pty Ltd | Crystal structure of human Janus Kinase 2 (JAK2) and uses thereof |
EP2251341A1 (en) | 2005-07-14 | 2010-11-17 | Astellas Pharma Inc. | Heterocyclic Janus kinase 3 inhibitors |
JP5071374B2 (en) | 2005-07-14 | 2012-11-14 | アステラス製薬株式会社 | Heterocyclic Janus Kinase 3 Inhibitor |
EP1919924A2 (en) | 2005-08-16 | 2008-05-14 | Irm, Llc | Compounds and compositions as protein kinase inhibitors |
JP2009509964A (en) * | 2005-09-23 | 2009-03-12 | メモリー・ファーマシューティカルズ・コーポレイション | Indazoles, benzothiazoles, benzisoxazoles, pyrazolopyridines, isothiazolopyridines, and their production and use |
US8106066B2 (en) * | 2005-09-23 | 2012-01-31 | Memory Pharmaceuticals Corporation | Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, pyrazolopyridines, isothiazolopyridines, and preparation and uses thereof |
JP4551962B2 (en) | 2005-09-23 | 2010-09-29 | コーリー ファーマシューティカル グループ,インコーポレイテッド | Process for 1H-imidazo [4,5-c] pyridine and analogs thereof |
EP1954290B1 (en) | 2005-11-22 | 2012-07-25 | Merck Sharp & Dohme Corp. | Tricyclic compounds useful as inhibitors of kinases |
TW200801008A (en) | 2005-12-29 | 2008-01-01 | Abbott Lab | Protein kinase inhibitors |
EP2029541B1 (en) | 2006-04-03 | 2009-12-30 | F. Hoffmann-Roche AG | Process for preparation of enantiomerically enriched cyclic beta-aryl or heteroaryl carboxylic acids |
WO2007143434A2 (en) | 2006-05-31 | 2007-12-13 | Takeda San Diego, Inc. | Indazole and isoindole derivatives as glucokinase activating agents |
BRPI0716439B8 (en) | 2006-08-14 | 2021-05-25 | Boehringer Ingelheim Int | pharmaceutical delivery systems comprising flibanserin, process for preparation and use thereof |
US8063225B2 (en) | 2006-08-14 | 2011-11-22 | Chembridge Corporation | Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders |
CA2665214A1 (en) | 2006-10-06 | 2008-05-29 | Abbott Laboratories | Novel imidazothiazoles and imidazoxazoles |
KR20090106604A (en) | 2007-01-12 | 2009-10-09 | 아스텔라스세이야쿠 가부시키가이샤 | Condensed pyridine compound |
CN101230059B (en) * | 2007-01-23 | 2011-08-17 | 上海恒瑞医药有限公司 | Bicycle aza alkyl derivative, preparation method and use in medicine thereof |
EP2108019A2 (en) | 2007-01-30 | 2009-10-14 | Biogen Idec MA, Inc. | 1-h-pyrazolo[3,4b]pyrimidine derivatives and their use as modulators of mitotic kinases |
WO2008112695A2 (en) | 2007-03-12 | 2008-09-18 | Irm Llc | Pyrazolo [3,4-d] pyrimidines and 1, 2, 5, 6-tetraaza- as- indacenes as protein kinase inhibitors for cancer treatment |
US7723343B2 (en) | 2007-03-30 | 2010-05-25 | King Pharmaceuticals Research And Development, Inc. | Adenosine A2A receptor antagonists |
SI2152250T1 (en) | 2007-05-07 | 2020-06-30 | Evonik Operations Gmbh | Solid dosage forms comprising an enteric coating with accelerated drug release |
EP2152712B1 (en) | 2007-05-11 | 2012-01-11 | Pfizer Inc. | Amino-heterocyclic compounds |
WO2009005675A1 (en) | 2007-06-28 | 2009-01-08 | Abbott Laboratories | Novel triazolopyridazines |
US20090022789A1 (en) | 2007-07-18 | 2009-01-22 | Supernus Pharmaceuticals, Inc. | Enhanced formulations of lamotrigine |
BRPI0908494A2 (en) | 2008-02-25 | 2015-08-11 | Hoffmann La Roche | Pyrrolopyrazine kinase inhibitors |
JP5485178B2 (en) | 2008-02-25 | 2014-05-07 | エフ.ホフマン−ラ ロシュ アーゲー | Pyrrolopyrazine kinase inhibitor |
EP2250172B1 (en) | 2008-02-25 | 2011-08-31 | F. Hoffmann-La Roche AG | Pyrrolopyrazine kinase inhibitors |
WO2009108827A1 (en) | 2008-02-29 | 2009-09-03 | Wyeth | Fused tricyclic pyrazolo[1, 5-a]pyrimidines, methods for preparation and uses thereof |
JP2011515438A (en) | 2008-03-28 | 2011-05-19 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Method of producing acid pellet |
UA106045C2 (en) | 2008-06-10 | 2014-07-25 | Еббві Інк. | Tricyclic compounds |
WO2010003133A2 (en) | 2008-07-03 | 2010-01-07 | Exelixis Inc. | Cdk modulators |
CN101638423B (en) * | 2008-07-29 | 2012-09-05 | 常州高新技术产业开发区三维工业技术研究所有限公司 | Phloridzin derivative as well as preparation method and application thereof |
EP2492267B1 (en) | 2009-02-24 | 2014-11-26 | Merck Sharp & Dohme Corp. | Indole derivatives as CRTH2 receptor antagonists in combination with a second active ingredient |
WO2010117796A2 (en) | 2009-03-30 | 2010-10-14 | Codexis, Inc. | Processes for the preparation of alpha-chloroketones from carboxylic acids |
US20120034250A1 (en) | 2009-04-14 | 2012-02-09 | Astellas Pharma Inc. | Condensed pyrrolopyridine derivative |
CN101904814A (en) | 2009-06-04 | 2010-12-08 | 上海恒瑞医药有限公司 | Preparation method of drug loaded emulsion |
FR2947276B1 (en) | 2009-06-24 | 2012-10-26 | Seppic Sa | COSMETIC COMPOSITION BASED ON ION EXCHANGE RESINS LOADED WITH LIPOAMINOACIDES |
US8361962B2 (en) | 2009-07-27 | 2013-01-29 | Roche Palo Alto Llc | Tricyclic inhibitors of JAK |
US9078830B2 (en) | 2009-07-31 | 2015-07-14 | Ranbaxy Laboratories Limited | Multi-layered, multiple unit pharmaceutical compositions |
CN102711476B (en) | 2009-12-01 | 2014-12-03 | Abbvie公司 | Novel tricyclic compounds |
JP2013512282A (en) | 2009-12-01 | 2013-04-11 | アボット・ラボラトリーズ | New tricyclic compounds |
US20130034604A1 (en) | 2010-05-14 | 2013-02-07 | Alembic Pharmaceuticals Limited | Extended release formulations of desvenlafaxine base |
TW201201801A (en) | 2010-06-09 | 2012-01-16 | Presidio Pharmaceuticals Inc | Inhibitors of HCV NS5A protein |
WO2011156698A2 (en) | 2010-06-11 | 2011-12-15 | Abbott Laboratories | NOVEL PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS |
JP5998142B2 (en) | 2010-09-27 | 2016-09-28 | アボット ゲーエムベーハー ウント カンパニー カーゲー | Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors |
US9011912B2 (en) | 2010-10-07 | 2015-04-21 | Abon Pharmaceuticals, Llc | Extended-release oral dosage forms for poorly soluble amine drugs |
WO2012149280A2 (en) | 2011-04-29 | 2012-11-01 | Abbott Laboratories | Novel tricyclic compounds |
US20130072470A1 (en) | 2011-09-21 | 2013-03-21 | Abbvie Inc. | Novel tricyclic compounds |
FR2991171B1 (en) | 2012-06-01 | 2014-05-23 | Galderma Res & Dev | PROCESS FOR THE PREPARATION OF A DERMATOLOGICAL COMPOSITION COMPRISING OLEOSOMES |
WO2014004863A2 (en) | 2012-06-27 | 2014-01-03 | Alzheimer's Institute Of America, Inc. | Compounds, compositions, and therapeutic uses thereof |
SG11201507351PA (en) | 2013-03-15 | 2015-10-29 | Global Blood Therapeutics Inc | Compounds and uses thereof for the modulation of hemoglobin |
JP6041823B2 (en) | 2013-03-16 | 2016-12-14 | ファイザー・インク | Tofacitinib oral sustained release dosage form |
EP3060234A1 (en) | 2013-10-24 | 2016-08-31 | AbbVie Inc. | Jak1 selective inhibitor and uses thereof |
AU2015308878A1 (en) | 2014-08-27 | 2017-03-02 | Abbvie Inc. | Topical formulation |
WO2016198983A1 (en) | 2015-06-09 | 2016-12-15 | Bend Research Inc. | Formulations to achieve rapid dissolution of drug from spray-dried dispersions in capsules |
JP2018527337A (en) | 2015-08-13 | 2018-09-20 | ファイザー・インク | Bicyclic fused heteroaryl or aryl compounds |
CN107949559B (en) | 2015-08-27 | 2020-12-11 | 辉瑞公司 | Bicyclic fused heteroaryl or aryl compounds as IRAK4 modulators |
CN116270645A (en) * | 2015-10-16 | 2023-06-23 | 艾伯维公司 | Process for preparing imidazo [1,2-a ] pyrrolo [2,3-e ] pyrazines and solid forms thereof |
US11365198B2 (en) | 2015-10-16 | 2022-06-21 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
US10550126B2 (en) | 2015-10-16 | 2020-02-04 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
US11512092B2 (en) | 2015-10-16 | 2022-11-29 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
US11524964B2 (en) | 2015-10-16 | 2022-12-13 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
IL259693B (en) | 2015-11-30 | 2022-07-01 | Anacor Pharmaceuticals Inc | Topical pharmaceutical formulations for treating inflammatory-related conditions |
WO2017126488A1 (en) | 2016-01-18 | 2017-07-27 | 持田製薬株式会社 | Psoriasis treatment composition and treatment method |
WO2017143014A1 (en) | 2016-02-16 | 2017-08-24 | Brian Kim | Jak inhibitors and uses thereof |
SG11201811760VA (en) | 2016-07-06 | 2019-01-30 | Durect Corp | Oral dosage form with drug composition, barrier layer and drug layer |
JP2020510016A (en) | 2017-03-09 | 2020-04-02 | アッヴィ・インコーポレイテッド | Methods for treating Crohn's disease and ulcerative colitis |
US11564922B2 (en) | 2017-03-09 | 2023-01-31 | Abbvie Inc. | Methods of treating crohn's disease and ulcerative colitis |
-
2016
- 2016-10-17 CN CN202211671776.7A patent/CN116270645A/en active Pending
- 2016-10-17 BR BR122022024925-6A patent/BR122022024925B1/en active IP Right Grant
- 2016-10-17 RU RU2018117889A patent/RU2018117889A/en unknown
- 2016-10-17 SG SG10201913989QA patent/SG10201913989QA/en unknown
- 2016-10-17 SG SG10201913997WA patent/SG10201913997WA/en unknown
- 2016-10-17 SG SG11201802990RA patent/SG11201802990RA/en unknown
- 2016-10-17 CA CA3123260A patent/CA3123260A1/en active Pending
- 2016-10-17 CA CA3002220A patent/CA3002220C/en active Active
- 2016-10-17 WO PCT/US2016/057372 patent/WO2017066775A1/en active Application Filing
- 2016-10-17 SG SG10201913987UA patent/SG10201913987UA/en unknown
- 2016-10-17 EP EP23151673.3A patent/EP4219503A1/en active Pending
- 2016-10-17 CN CN201680070259.0A patent/CN108368121B/en active Active
- 2016-10-17 CN CN202211671778.6A patent/CN116270646A/en active Pending
- 2016-10-17 BR BR112018007677-5A patent/BR112018007677A2/en active Search and Examination
- 2016-10-17 MX MX2018004605A patent/MX2018004605A/en unknown
- 2016-10-17 AU AU2016340167A patent/AU2016340167B2/en active Active
- 2016-10-17 SG SG10201913999PA patent/SG10201913999PA/en unknown
- 2016-10-17 SG SG10201913993QA patent/SG10201913993QA/en unknown
- 2016-10-17 SG SG10201913986YA patent/SG10201913986YA/en unknown
- 2016-10-17 CN CN202211671688.7A patent/CN116284011A/en active Pending
- 2016-10-17 JP JP2018517576A patent/JP6770775B2/en active Active
- 2016-10-17 KR KR1020187013644A patent/KR20180081523A/en not_active Application Discontinuation
- 2016-10-17 SG SG10201913990RA patent/SG10201913990RA/en unknown
- 2016-10-17 US US15/295,561 patent/US20170129902A1/en not_active Abandoned
- 2016-10-17 EP EP16788358.6A patent/EP3362455A1/en not_active Withdrawn
-
2017
- 2017-08-21 US US15/682,451 patent/US9879018B2/en active Active
- 2017-08-21 US US15/682,457 patent/US9879019B2/en active Active
- 2017-11-03 US US15/803,538 patent/US9951080B2/en active Active
- 2017-12-29 US US15/857,892 patent/US9963459B1/en active Active
-
2018
- 2018-02-07 US US15/891,306 patent/US10017517B2/en active Active
- 2018-02-07 US US15/891,012 patent/US20190023714A1/en not_active Abandoned
- 2018-02-28 US US15/908,347 patent/US10344036B2/en active Active
- 2018-04-04 US US15/945,231 patent/US10202394B2/en active Active
- 2018-04-04 US US15/945,225 patent/US10202393B2/en active Active
- 2018-04-11 IL IL258654A patent/IL258654A/en unknown
- 2018-04-13 MX MX2021013812A patent/MX2021013812A/en unknown
-
2019
- 2019-01-29 HK HK19101482.2A patent/HK1263380A1/en unknown
- 2019-06-26 US US16/453,684 patent/US10519164B2/en active Active
- 2019-07-01 US US16/458,622 patent/US10597400B2/en active Active
- 2019-10-17 US US16/656,237 patent/US20200291040A1/en not_active Abandoned
-
2020
- 2020-02-11 US US16/787,251 patent/US10730883B2/en active Active
- 2020-06-18 US US16/905,667 patent/US10981923B2/en active Active
- 2020-08-03 US US16/983,701 patent/US10981924B2/en active Active
- 2020-09-24 JP JP2020159855A patent/JP7358317B2/en active Active
-
2021
- 2021-02-24 US US17/184,194 patent/US20210363149A1/en not_active Abandoned
- 2021-04-14 US US17/230,288 patent/US11186584B2/en active Active
- 2021-04-14 US US17/230,418 patent/US11198697B1/en active Active
- 2021-05-28 IL IL283531A patent/IL283531A/en unknown
- 2021-09-24 AU AU2021236570A patent/AU2021236570B2/en active Active
-
2022
- 2022-05-13 JP JP2022079226A patent/JP2022107001A/en active Pending
- 2022-05-27 US US17/827,054 patent/US11535624B2/en active Active
- 2022-09-23 US US17/951,334 patent/US11661425B2/en active Active
- 2022-09-23 US US17/951,332 patent/US11680069B2/en active Active
-
2023
- 2023-01-06 US US18/094,266 patent/US11718627B2/en active Active
- 2023-01-06 US US18/094,263 patent/US11773105B2/en active Active
- 2023-02-27 US US18/174,738 patent/US11780847B1/en active Active
- 2023-02-27 US US18/174,736 patent/US11787815B1/en active Active
- 2023-03-01 US US18/176,647 patent/US11795175B2/en active Active
- 2023-06-02 US US18/328,350 patent/US20230312595A1/en active Pending
- 2023-06-02 US US18/328,325 patent/US20240034740A1/en active Pending
- 2023-06-06 US US18/329,986 patent/US20230348481A1/en active Pending
- 2023-06-06 US US18/329,988 patent/US20230322794A1/en active Pending
- 2023-06-06 US US18/329,980 patent/US20230331735A1/en active Pending
- 2023-06-12 JP JP2023096042A patent/JP2023113917A/en active Pending
- 2023-07-28 US US18/361,582 patent/US20230374027A1/en not_active Abandoned
- 2023-09-18 US US18/369,272 patent/US20240010656A1/en active Pending
- 2023-10-19 AU AU2023251492A patent/AU2023251492A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL283531A (en) | Processes for the preparation of (3s,4r)-3-ethyl-4-(3h-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof | |
IL268737A (en) | Processes for the preparation of benzodiazepine derivatives | |
IL266170A (en) | Process for the preparation of pyrazolo[1,5-a]pyrimidines and salts thereof | |
EP3468973A4 (en) | Solid forms of venetoclax and processes for the preparation of venetoclax | |
EP3710009A4 (en) | Processes for the resolution of benzodiazepin-2-one and benzoazepin-2-one derivatives | |
IL250280B (en) | Spiro[3h-indole-3,2´-pyrrolidin]-2(1h)-one compounds, derivatives thereof and pharmaceutical compositions comprising them | |
IL270909A (en) | Imidazo[1,2-a]pyrazine modulators of the adenosine a2a receptor | |
EP3546460A4 (en) | Pyrimido[5,4-b]indolizine or pyrimido[5,4-b]pyrrolizine compound, preparation method and use thereof | |
IL262257B (en) | 1,5-dihydro-4h-pyrazolo[3,4-d]pyrimidin-4-ones and 1,5-dihydro-4h-pyrazolo[4,3-c]pyridin-4-ones as pde1 inhibitors | |
EP3120994A4 (en) | Hollow structural body and component for vehicles | |
HK1247203A1 (en) | Substituted imidazo [1, 2-a]pyridin-2-ylamine compounds, and pharmaceutical compositions and methods of use thereof | |
HK1256044A1 (en) | Pyrido[1,2-a]pyrimidone analog, crystal form thereof, intermediate thereof and preparation method therefor | |
PL3135110T3 (en) | 1,7-diaryl-1,6-heptadien-3,5-dion derivatives, methods of making and using the same | |
IL251107B (en) | Derivatives of-[2h]-imidazo-[1,2-a]pyrazolo[4,3-e]pyrimidin-4(5h)-one, pharmaceutical composition comprising them and their use in treating cns sisorderes. | |
GB201802644D0 (en) | Monocyclic,thieno, pyrido and pyrrolo pyrimidine compounds and methods of use and manufacture of the same | |
SG11202001266XA (en) | Process for the preparation of low haze and color stable styrenic polymers | |
IL253427B (en) | Pyrazolo[3,4-d]pyrimidin derivative and its use for the treatment of leishmaniasis | |
HK1257427A1 (en) | A process for the preparation of 2-pyrazolo[1,5-a]pyrazin-2-ylpyrido[1,2-a]pyrimidin-4-one | |
IL274560A (en) | Process for the preparation of raltegravir | |
RS63004B1 (en) | Crystal of pyrido[3, 4-d]pyrimidine derivative or solvate thereof | |
EP3302784A4 (en) | Adsorbent bioprocessing clarification agents and methods of making and using the same |